Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)
Jai N. Patel(Levine Cancer Institute), Howard L. McLeod(Unknown), Michael J. Morris(Dana-Farber Cancer Institute), Kouros Owzar(Duke University), Michael J. Kelley(Durham VA Health Care System), Flora Mulkey(Sherwin Williams (United States)), Susan Halabi(Duke Medical Center), Mark J. Ratain(University of Chicago), Daniel L. Hertz(GTx (United States)), Chen Jiang, John F. Mahoney(University of Pittsburgh), William Kevin Kelly(Thomas Jefferson University), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Paula N. Friedman(University of North Carolina at Chapel Hill), Eric J. Small(CancerCare Manitoba)
Cited by 35
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k